Results 41 to 50 of about 20,950 (257)

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. [PDF]

, 2016
OBJECTIVE: To evaluate the effect of secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic changes through 2 years in patients with ankylosing spondylitis (AS). METHODS: In the phase III MEASURE 1 study, patients were
Baeten, D, Baraliakos, X, Braun, J, Deodhar, A, Emery, P, Martin, R, MEASURE 1 study group, Mpofu, S, Readie, A, Richards, HB, Sieper, J   +10 more
core   +1 more source

Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head‐to‐Head Randomized Phase IIIb Study

Arthritis & Rheumatology
Spinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (SpA). The objective of the phase IIIb SURPASS study was to compare spinal radiographic progression in patients with radiographic axial SpA treated with ...
X. Baraliakos, Mikkel Østergaard, Denis Poddubnyy, D. van der Heijde, A. Deodhar, Pedro M. Machado, V. Navarro-Compán, Kay-Geert A Hermann, M. Kishimoto, Eun Young Lee, L. Gensler, U. Kiltz, M. Eigenmann, P. Pertel, A. Readie, H. Richards, B. Porter, J. Braun   +17 more
semanticscholar   +1 more source

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Dermatologic Therapy, 2023
Biologics have revolutionized the management of psoriasis, but response to treatment varies. Loss of treatment efficacy may occur over time, requiring treatment switching or escalation.
T. Fitzgerald, M. Zhdanava, D. Pilon, Aditi Shah, A. Hilts, P. Lefebvre, S. Feldman   +6 more
semanticscholar   +1 more source

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study

ACR Open Rheumatology, 2020
Objective To report the 5‐year efficacy and safety of secukinumab in the treatment of patients with psoriatic arthritis (PsA) in the FUTURE 1 study (NCT01392326).
Philip J. Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Juergen Rech, Stephen Hall, Piet Geusens, Pascale Pellet, Eumorphia Maria Delicha, Luminita Pricop, Shephard Mpofu, on behalf of the FUTURE 1 study group   +11 more
doaj   +1 more source

Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs

Вопросы современной педиатрии, 2021
The article shows the key role of IL-17 in the psoriasis pathogenesis and the opportunities of its management via monoclonal antibodies product secukinumab.
Leyla S. Namazova-Baranova, Andrey L. Bakulev, Nikolay N. Murachkin, Lyudmila N. Nam, Roman A. Ivanov   +4 more
doaj   +1 more source

Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab [PDF]

, 2020
Switching of biologic agents in treatment of plaque psoriasis is a common strategy. Only a few studies are available on switching between IL17A-blockers.
Amschler, K, Gerdes, S, Mohr, J, Mössner, R, Phillip, S, Poortinga, S, Wilsmann-Theis, D   +6 more
core   +1 more source

Comparison of Bayesian and frequentist group-sequential clinical trial designs [PDF]

, 2020
Background: There is a growing interest in the use of Bayesian adaptive designs in late-phase clinical trials. This includes the use of stopping rules based on Bayesian analyses in which the frequentist type I error rate is controlled as in frequentist
Gates, Simon, Ryan, Elizabeth G., Stallard, Nigel, Todd, Sue   +3 more
core   +2 more sources

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

Clinical, Cosmetic and Investigational Dermatology
Background The treatment of hidradenitis suppurativa (HS) has always been a real challenge for dermatologists; to date, adalimumab the only biologic drug approved for HS is adalimumab, an anti-tumor necrosis factor (TNF)-α drug, the approval of this drug
F. Martora, C. Marasca, S. Cacciapuoti, Federica Fariello, L. Potestio, T. Battista, M. Scalvenzi, M. Megna   +7 more
semanticscholar   +1 more source

Secukinumab in patients with moderate to severe hidradenitis suppurativa based on prior biologic exposure: An efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.

British Journal of Dermatology
BACKGROUND Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease associated with a substantial disease burden. Secukinumab has previously been reported to have sustained efficacy with a favourable safety profile in patients with moderate ...
C. C. Zouboulis, T. Passeron, David M. Pariser, Magdalena B. Wozniak, Xianjun Li, Lorenz Uhlmann, Iryna Lobach, Angela Llobet Martinez, Shoba Ravichandran, Ivette Alarcon, A. Offidani, M. Alam, P. Mendes-Bastos   +12 more
semanticscholar   +1 more source

Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy

Journal of dermatological treatment (Print), 2023
Background Long-term real-life data on secukinumab use in psoriasis are limited. Objectives Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in real-life.
S. Dastoli, Maria Passante, F. Loconsole, E. Mortato, A. Balato, V. Piccolo, C. Guarneri, L. Macca, E. Provenzano, G. Valenti, D. D'Amico, G. Micali, M. Musumeci, Giovanni Palazzo, C. Foti, P. Romita, G. Fabbrocini, M. Megna, I. Sammarra, L. Bennardo, C. Patruno   +20 more
semanticscholar   +1 more source